About fibrosis markers - how they can use Mac-2 blood tests
Tig said
Jun 13, 2017
That was interesting, thanks, Chuck! I am continuously reminded of all the different proteins we carry around that provide so much diagnostic information. This same protein you referenced has been shown to provide information on post hepatectomy liver failure in HCC patients. It also drops following HCV SVR, so there may be a simpler way to test and monitor treatment efficacy.
All this winning is exciting!!
Canuck said
Jun 13, 2017
Just yet another helpful tool in judging fibrosis.
Published inGastroenterology
Journal Scan / Research · June 09, 2017
Mac-2 Binding Protein Glycosylation Isomer Effective for Identifying Liver Fibrosis in Patients With Hepatitis C
BMC Gastroenterology
TAKE-HOME MESSAGE
- Patients with chronic hepatitis C and a cohort of healthy controls underwent evaluation of serum M2BPGi levels prior to a FibroScan test of liver fibrosis to evaluate the efficacy of M2BPGi in identifying hepatic fibrosis. In the cohort with hepatitis C, the median serum M2BPGi level increased as the fibrosis score increased, and the M2BPGi level could effectively distinguish hepatitis C patients from controls. M2BPGi was significantly associated with liver stiffness measurement (P < .001). The optimal cutoff values for serum M2BPGi were 0.945 for patients with F2 and 1.355 for patients with F4. M2BPGi was superior to all other invasive markers and had the greatest specificity for diagnosing cirrhosis.
- The use of serum M2BPGi levels is a simple but reliable diagnostic aid for identifying fibrosis in patients with chronic hepatitis C infection.
BACKGROUND
Mac-2 Binding Protein Glycosylation isomer (M2BPGi) is a novel serological glyco-biomarker for staging liver fibrosis. Here, we aimed to evaluate the efficiency of serum M2BPGi in identifying liver fibrosis stages in Chinese patients with chronic hepatitis C infection.
METHODS
Serum M2BPGi levels were evaluated in 680 patients with chronic hepatitis C and 164 healthy controls who underwent the Fibro Scan® test of liver fibrosis. The diagnostic accuracy of serum M2BPGi values was compared to that of other fibrosis markers, including Fibro Scan®, the aspartate transaminase to platelet ratio index (APRI), the fibrosis index based on four factors (FIB4), and the gamma-glutamyltranspeptidase to platelet ratio (GPR).
RESULTS
Among the chronic hepatitis C patients, the median serum M2BPGi level increased with increasing fibrosis score as follows: 0.88 (<F2), 1.70 (F2/F3), and 5.68 (cirrhosis). M2BPGi concentrations could also distinguish between healthy controls (0.38 ± 0.24) and hepatitis C patients (1.57 ± 2.28). After adjusting for potential confounders, M2BPGi was the most significant factor associated with the liver stiffness measurement (effect size = 0.275, P < 0.001). The optimum cutoff values of serum M2BPGi for patients with F2 and F4 were 0.945 and 1.355, respectively. The area under the curve of serum M2BPGi for prediction of significant fibrosis (F>4) using was comparable to that of APRI (0.892 vs. 0.873), while it was superior to that of other alternative markers, including FIB4 (0.818) and GPR (0.851). Compared with other non-invasive markers, M2BPGi had the greatest specificity for diagnosing cirrhosis and cirrhosis in hepatitis C patients.
CONCLUSIONS
Our results suggest that the level of serum M2BPGi would be a simple and reliable diagnostic tool for identifying liver fibrosis stage in Chinese patients with chronic hepatitis.
That was interesting, thanks, Chuck! I am continuously reminded of all the different proteins we carry around that provide so much diagnostic information. This same protein you referenced has been shown to provide information on post hepatectomy liver failure in HCC patients. It also drops following HCV SVR, so there may be a simpler way to test and monitor treatment efficacy.
All this winning is exciting!!
Just yet another helpful tool in judging fibrosis.
Published in Gastroenterology
Journal Scan / Research · June 09, 2017
Mac-2 Binding Protein Glycosylation Isomer Effective for Identifying Liver Fibrosis in Patients With Hepatitis C
BMC Gastroenterology
TAKE-HOME MESSAGE
- Patients with chronic hepatitis C and a cohort of healthy controls underwent evaluation of serum M2BPGi levels prior to a FibroScan test of liver fibrosis to evaluate the efficacy of M2BPGi in identifying hepatic fibrosis. In the cohort with hepatitis C, the median serum M2BPGi level increased as the fibrosis score increased, and the M2BPGi level could effectively distinguish hepatitis C patients from controls. M2BPGi was significantly associated with liver stiffness measurement (P < .001). The optimal cutoff values for serum M2BPGi were 0.945 for patients with F2 and 1.355 for patients with F4. M2BPGi was superior to all other invasive markers and had the greatest specificity for diagnosing cirrhosis.
- The use of serum M2BPGi levels is a simple but reliable diagnostic aid for identifying fibrosis in patients with chronic hepatitis C infection.
BACKGROUND
Mac-2 Binding Protein Glycosylation isomer (M2BPGi) is a novel serological glyco-biomarker for staging liver fibrosis. Here, we aimed to evaluate the efficiency of serum M2BPGi in identifying liver fibrosis stages in Chinese patients with chronic hepatitis C infection.
METHODS
Serum M2BPGi levels were evaluated in 680 patients with chronic hepatitis C and 164 healthy controls who underwent the Fibro Scan® test of liver fibrosis. The diagnostic accuracy of serum M2BPGi values was compared to that of other fibrosis markers, including Fibro Scan®, the aspartate transaminase to platelet ratio index (APRI), the fibrosis index based on four factors (FIB4), and the gamma-glutamyltranspeptidase to platelet ratio (GPR).
RESULTS
Among the chronic hepatitis C patients, the median serum M2BPGi level increased with increasing fibrosis score as follows: 0.88 (<F2), 1.70 (F2/F3), and 5.68 (cirrhosis). M2BPGi concentrations could also distinguish between healthy controls (0.38 ± 0.24) and hepatitis C patients (1.57 ± 2.28). After adjusting for potential confounders, M2BPGi was the most significant factor associated with the liver stiffness measurement (effect size = 0.275, P < 0.001). The optimum cutoff values of serum M2BPGi for patients with F2 and F4 were 0.945 and 1.355, respectively. The area under the curve of serum M2BPGi for prediction of significant fibrosis (F>4) using was comparable to that of APRI (0.892 vs. 0.873), while it was superior to that of other alternative markers, including FIB4 (0.818) and GPR (0.851). Compared with other non-invasive markers, M2BPGi had the greatest specificity for diagnosing cirrhosis and cirrhosis in hepatitis C patients.
CONCLUSIONS
Our results suggest that the level of serum M2BPGi would be a simple and reliable diagnostic tool for identifying liver fibrosis stage in Chinese patients with chronic hepatitis.